CY1110699T1 - Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο - Google Patents

Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο

Info

Publication number
CY1110699T1
CY1110699T1 CY20101100054T CY101100054T CY1110699T1 CY 1110699 T1 CY1110699 T1 CY 1110699T1 CY 20101100054 T CY20101100054 T CY 20101100054T CY 101100054 T CY101100054 T CY 101100054T CY 1110699 T1 CY1110699 T1 CY 1110699T1
Authority
CY
Cyprus
Prior art keywords
certification
site
capacity
connection
fields containing
Prior art date
Application number
CY20101100054T
Other languages
English (en)
Inventor
Peter Kufer
Tobias Raum
Katrin Borschert
Florian Zettl
Ralf LUTTERBÜSE
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of CY1110699T1 publication Critical patent/CY1110699T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μέθοδο πιστοποίησης πεδίων θέσης σύνδεσης που διατηρούν την ικανότητα σύνδεσης προς έναν επίτοπο όταν τοποθετούνται C-τερματικά από τουλάχιστον ένα περαιτέρω πεδίο σε ένα ανασυνδυασμένο δισθενές ή πολυσθενές πολυπεπτίδιο. Η παρούσα εφεύρεση περαιτέρω αφορά ένα KIT που περιλαμβάνει συστατικά, όπως πάνελ ανασυνδυασμένων φορέων βακτηριακών συλλογών, που μορφομετατρέπονται με ένα πάνελ ανασυνδυασμένων φορέων, που είναι χρήσιμο στην διεξαγωγή της μεθόδου της εφεύρεσης. Περαιτέρω, περιγράφονται πεδία θέσης σύνδεσης, πρωτεΐνες σύντηξης που λαμβάνονται με την μέθοδο της εφεύρεσης, καθώς επίσης ομοιάζοντα με αντίσωμα μόρια που περιλαμβάνουν τέτοια πεδία και πρωτεΐνες. Περαιτέρω παρέχονται φαρμακευτικές και διαγνωστικές συνθέσεις που περιέχουν τις ανωτέρω περιγραφείσες πρωτεΐνες σύντηξης και πολυπεπτίδια.
CY20101100054T 1997-11-17 2010-01-19 Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο CY1110699T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97120096 1997-11-17
EP98963460A EP1032660B1 (en) 1997-11-17 1998-11-16 Method of identifying binding site domains that retain the capacity of binding to an epitop

Publications (1)

Publication Number Publication Date
CY1110699T1 true CY1110699T1 (el) 2015-06-10

Family

ID=8227629

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100054T CY1110699T1 (el) 1997-11-17 2010-01-19 Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο

Country Status (13)

Country Link
US (1) US7435549B1 (el)
EP (1) EP1032660B1 (el)
JP (2) JP4327350B2 (el)
AT (1) ATE447613T1 (el)
AU (1) AU1873199A (el)
CA (1) CA2309679C (el)
CY (1) CY1110699T1 (el)
DE (1) DE69841273D1 (el)
DK (1) DK1032660T3 (el)
ES (1) ES2334184T3 (el)
HK (1) HK1031740A1 (el)
PT (1) PT1032660E (el)
WO (1) WO1999025818A1 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420110B1 (en) * 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
GB9917027D0 (en) * 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
CN1423700A (zh) * 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
WO2002010417A2 (en) * 2000-08-02 2002-02-07 Xencor Methods and compositions for the construction and use of viral envelops as display particles
RU2005137325A (ru) 2003-05-31 2006-09-10 Микромет Аг (De) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
PL1673398T3 (pl) 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
EP2102239B1 (en) 2006-11-30 2012-04-25 Research Development Foundation Improved immunoglobulin libraries
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
WO2014031174A1 (en) 2012-08-24 2014-02-27 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
ES2960807T3 (es) 2013-10-11 2024-03-06 Us Health Anticuerpos contra TEM8 y su uso
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP3875481A1 (en) 2014-11-14 2021-09-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
EP3271389B8 (en) 2015-03-20 2020-04-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to gp120 and their use
WO2017062748A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
EP3371214A1 (en) 2015-11-03 2018-09-12 THE UNITED STATES OF AMERICA, represented by the S Neutralizing antibodies to hiv-1 gp41 and their use
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
KR20190022752A (ko) 2016-06-27 2019-03-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
EP3724223A1 (en) 2018-01-02 2020-10-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
WO2020227228A2 (en) 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
BR112023008629A2 (pt) 2020-11-06 2023-10-03 Amgen Inc Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
US11692039B2 (en) 2020-12-31 2023-07-04 Innate Pharma Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123
EP4291226A1 (en) 2021-02-09 2023-12-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Antibodies targeting the spike protein of coronaviruses
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
AU2022345251A1 (en) 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024138155A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE69233367T2 (de) * 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
AU685753B2 (en) * 1992-09-04 1998-01-29 Scripps Research Institute, The Phagemids coexpressing a surface receptor and a surface heterologous protein
US5837242A (en) * 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
ATE232902T1 (de) 1994-03-17 2003-03-15 Merck Patent Gmbh Anti-egfr einkettige fvs und anti-egfr antikoerper
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
DK0826696T3 (da) * 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
WO1999006587A2 (en) * 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex

Also Published As

Publication number Publication date
EP1032660A1 (en) 2000-09-06
ES2334184T3 (es) 2010-03-05
US7435549B1 (en) 2008-10-14
DK1032660T3 (da) 2010-01-18
DE69841273D1 (de) 2009-12-17
EP1032660B1 (en) 2009-11-04
AU1873199A (en) 1999-06-07
JP4327350B2 (ja) 2009-09-09
PT1032660E (pt) 2009-12-28
CA2309679C (en) 2010-07-20
WO1999025818A1 (en) 1999-05-27
JP4977156B2 (ja) 2012-07-18
JP2002508924A (ja) 2002-03-26
CA2309679A1 (en) 1999-05-27
HK1031740A1 (en) 2001-06-22
JP2009148280A (ja) 2009-07-09
ATE447613T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
CY1110699T1 (el) Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο
KR950032280A (ko) 라파마이신의 주효 단백질
NO20000934D0 (no) Adipocyttspesifikke proteinhomologer
WO2004065416A3 (en) Synthetic antibody phage libraries
ATE322909T1 (de) Antikörper gegen verkürzten vegf-d und deren verwendungen
ATE352618T1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
AU4474497A (en) Methods and means for selecting peptides and proteins having specific affinity for a target
DE69531302D1 (de) Zellsystem mit einer spezifischen wechselwirkung von peptid-bindenden paaren
CA2124953A1 (en) Peptides related to prion proteins
ATE151113T1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE69632827D1 (de) Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen
ATE406439T1 (de) Eukaryontische signalsequenzen für polypeptid- expressions- und polypeptid- präsentationsbibliotheken
DE69834643D1 (de) Adipozyten-spezifische protein homologe
DE59914490D1 (de) Ein faktor viii-polypeptid mit faktor viii:c-aktivität
DE69434384D1 (de) Metalkomplexbildner
ATE172247T1 (de) Car-rezeptoren und verwandte moleküle und entsprechende methoden
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
EP2305710A3 (en) Synthetic antibody phage libraries
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
WO2004094615A3 (en) Prokaryotic collagen-like proteins and uses thereof
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
WO2000073446A3 (en) Adipocyte complement related protein homolog zacrp6
GB9929151D0 (en) Peptide and polypeptide display